GSK's asthma and COPD treatment 'Relvar Ellipta’ received sales approval from the Ministry of Food and Drug Safety

Published: 2014-07-21 14:22:17

Updated: 2014-07-21 14:22:17

GSK's asthma and chronic obstructive pulmonary disease (COPD) treatment 'Relvar Ellipta (fluticasone furoate + vilanterol), received sales approval from the Ministry of Food and Drug Safety.

'Relvar' is composed of inhaled corticosteroid (ICS) fluticasone furoate and long-acting beta-2 agonist (LABA) vilanterol. Through the new dry powder inhaler of 'El lipta', the effect of product lasts for ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.